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INTRODUCTION
Acetylsalicylic acid (a combination of sodium salicyla-
te with acetyl chloride), synthesized in an industrial 
environment in 1897, was introduced to the market 
as Aspirin® in 1899. For about 70 years, it represent-
ed the mainstay of analgesic/anti-infl ammatory drug 
therapy. Following several fundamental discoveries 
on its mechanism of action as an antiplatelet drug in 
the 1970s, aspirin has lived a second life as an anti-
thrombotic agent, becoming a fundamental compo-
nent of cerebrovascular and cardiovascular preventi-
on and treatment (1,2). Making a jump from a largely 
over-the-counter analgesic remedy to a life-saving 
prescription drug represents a success story of in-
dependent translational research. However, as with 
other cerebrovascular and cardiovascular preventi-
on strategies (e.g., blood pressure- or lipid-lowering 
drugs), low-dose aspirin can only reduce a fraction of 
all major vascular events. Similar to antihypertensive 
drugs or statins, the absolute benefi ts of aspirin are li-
nearly related to the underlying cerebrovascular and/
or cardiovascular risk of patients.
Although widely regarded as safe for patient-dire-
cted, over-the-counter use, aspirin is associated with 
a range of harms. Th ey vary in type and severity with 
dosage and duration of use, and with the underlying 
patient risk factors. By inhibiting cyclooxygenase-1 
enzyme activity, low-dose aspirin leads to mucosal 
damage to the gastrointestinal (GI) tract and causes 
erosions, ulcers, and bleeding (3-5). Cyclooxygena-
se-mediated antiplatelet eff ects also increase trivial to 
serious non-GI bleeding events, including intracranial 
bleeding events and hemorrhagic strokes (6,7).  Th e 
advisability of using aspirin for the primary preventi-
on of carebrovascular (CBVD) and cardiovascular di-
sease (CVD) events depends on accurately estimating 
harms associated with a specifi c prevention regimen 
and the absolute and relative variability in harms for 
any individual or targeted subpopulation.
Th e aim of this annotation is to report serious bleed-
ing-related harms from aspirin used for primary pre-
vention of CBVD and/or CVD.
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ACETYLSALICYLIC ACID IN PRIMARY 
CEREBROVASCULAR AND CARDIOVASCULAR 
PREVENTION
In primary CBVD and CVD prevention, in which the 
risk of developing atherothrombotic events is gene-
rally low, it is essential to estimate the individual base-
line risk of such events and balance it against the risk 
of adverse outcomes related to therapy.
Th e Framingham coronary heart disease (CHD) risk 
score (8), European Society of Cardiology and other 
societies on cardiovascular disease prevention in cli-
nical practice SCORE (Systematic Coronary Risk 
Evaluation) (9), and American College of Cardiology/
American Heart Association (AHA/ACC) Task Force 
risk equations (10) are commonly used tools to assess 
the baseline risk of undesirable treatment outcomes.
Th e respondents were ranked based on the ability to 
develop a coronary event (composite of myocardial 
infarction (MI) and coronary death) in 10-year pe-
riod as low (<10%), moderate (10% to 20%), or high 
(>20%) risk (8). Th e SCORE system estimates 10-year 
risk of a fatal atherosclerotic event, and individuals are 
considered at low risk with a SCORE <1%, at mode-
rate risk with a SCORE 1% and <5%, at high risk with 
a SCORE 5% and <10%, and at very high risk with a 
SCORE ≥10% (9).
Aspirin trials for primary cerebrovascular and cardio-
vascular prevention 
In 2009, Baigent et al. published a meta-analysis (11) 
that included the fi rst 6 primary CBVD and CVD 
prevention studies with about 95,000 respondents 
(12-17). Th ey found that, over a 10-year period, aspi-
rin therapy was associated with 6 fewer MI per 1,000 
CHD low-risk persons treated. Persons at moderate 
and high CHD risk treated with aspirin had a more 
signifi cantly reduced risk of MI (19 and 31 MIs per 
1,000 patients treated, respectively) (8). With respect 
to mortality, protective eff ect was found to be of si-
milar magnitude in persons at low and at moderate to 
high risk of CBVD and CVD. Aspirin therapy did not 
seem to have an eff ect on CBVD occurrence, and the 
overall reduction of CVDs was almost balanced by the 
increase in bleeding events throughout the baseline 
risk categories. 
Four additional meta-analyses were published in 2011 
and 2012 (18-21). Unlike previous investigations, these 
included patients who, although asymptomatic, were 
at a higher risk because of preexisting diabetes and/
or asymptomatic peripheral arterial disease (PAD). In 
these meta-analyses, all cause mortality (but not the 
mortality from CBVD and CVD) was slightly but con-
sistently reduced, which is consistent with the result of 
Anti-Th rombotic-Trialists meta-analysis (11). In a re-
cent research dealing with treatment strategies for pa-
tients with peripheral artery disease, it was confi rmed 
that there was no diff erence in the infl uence of aspirin 
and placebo on total, CBD and CVD mortality (22).
Th e Japanese Primary Prevention Project (JPPP) was 
designed to determine whether once-daily, low-dose, 
enteric-coated aspirin reduces total number of athe-
rosclerotic events (ischemic heart disease and stroke) 
compared with no aspirin in a total of 14,464 Japane-
se patients aged ≥60 with DM, hypertension, or dysli-
pidemia (23). Th e 5-year cumulative primary outcome 
event (death from MI, stroke, and other CVDs) rate was 
not signifi cantly diff erent between the groups (2.77% 
[95%CI, 2.40%-3.20%] for aspirin vs. 2.96% [95% CI, 
2.58%-3.40%] for no aspirin; HR, 0.94 [95% CI, 0.77-
1.15]; p=0.54). Aspirin signifi cantly reduced the inci-
dence of nonfatal MI (0.30 [95%CI, 0.19- 0.47] for as-
pirin vs. 0.58 [95% CI, 0.42-0.81] for no aspirin; HR, 
0.53 [95% CI, 0.31-0.91]; p=0.02) and transient ische-
mic attack (TIA) (0.26 [95%CI, 0.16-0.42] for aspirin vs. 
0.49 [95% CI, 0.35-0.69] for no aspirin; HR, 0.57 [95% 
CI, 0.32-0.99]; p=0.04), and signifi cantly increased the 
risk of extracranial hemorrhage requiring transfusion 
or hospitalization (0.86 [95% CI, 0.67-1.11] for aspirin 
vs. 0.51 [95% CI, 0.37-0.72] for no aspirin; HR, 1.85 
[95% CI, 1.22-2.81]; p=0.004). Once-daily 100-mg ta-
blet of enteric-coated aspirin did not signifi cantly re-
duce the risk of composite outcome of cardiovascular 
death, nonfatal stroke, and nonfatal MI among Japanese 
patients aged ≥60 with atherosclerotic risk factors (23).
Until recently, most of the previous studies (with the 
exception of JPPP) (23) on the use of aspirin in pri-
mary CBVD/CVD prevention included low-CVD risk 
patients. Unlike previous ones, the latest randomized 
controlled trials (RCTs) investigated the effi  cacy and 
safety of aspirin (100 mg/daily) versus placebo (or 
no aspirin) in subjects at a higher level of estimated 
CBVD and/or CVD risk. Th e primary effi  cacy outco-
me includes vascular death, nonfatal MI, and nonfatal 
stroke to be weighed against major bleeding (mainly 
GI and intracranial). Th e enrolled populations range 
from nondiabetic subjects with ≥2 or ≥3 risk factors, 
to elderly patients aged ≥70, or elderly with additional 
risk factors, and patients with diabetes mellitus (DM). 
Th e follow-up period was 4 to 7.5 years (24-26).
Despite the ever-increasing number of aspirin effi  cacy 
studies in primary CBVD and CVD involving a large 
number of patients, the results are still uneven or even 
controversial. Of the three recently published studies, 
ASCEND (24) ARRIVE (25) and ASPREE (26), the 
latter two showed no cardiovascular benefi t and mo-
dest, but statistically signifi cant excess in bleeding risk. 
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In the ASCEND survey, the adults with DM but no 
evident CVD has been randomly assigned to receive 
aspirin at a dose of 100 mg daily or placebo (24). Th e 
primary effi  cacy outcome was the fi rst serious vascular 
event (MI, stroke or TIA, or death from any vascular 
cause, excluding any confi rmed intracranial hemorr-
hage). Th e primary safety outcome was the fi rst major 
bleeding event (intracranial hemorrhage, GI bleeding, 
sight-threatening bleeding event in the eye, or other 
serious bleeding). A total of 15,480 middle-aged or ol-
der DM patients were included in the study. During 
a mean follow-up of 7.4 years, serious vascular events 
occurred in a signifi cantly lower percentage of partici-
pants in the aspirin group (8.5%) than in the placebo 
group (9.6%), and the diff erence was statistically signi-
fi cant (p=0.01). On the contrary, major bleeding events 
occurred in 4.1% of participants in the aspirin group, 
as compared with 3.2% in the placebo group (rate ratio, 
1.29; 95% CI, 1.09 to 1.52; p=0.003). Th e most common 
was GI bleeding. Th e authors of the study conclud-
ed that aspirin use prevented serious vascular events in 
DM patients with no evident CVD at trial entry (24). 
Aspirin also caused major (mostly GI) bleeding events, 
and therefore the absolute treatment benefi ts were lar-
gely counterbalanced by the bleeding hazard. 
Th e aim of ARRIVE trial was to assess the effi  cacy and 
safety of aspirin (100 mg daily) versus placebo in pa-
tients with a moderate estimated risk of fi rst cardiovas-
cular event (25). A total of 12,546 patients were enro-
lled in the study. Enrolled men were aged ≥55 and had 
≥2 CV risk factors, while enrolled women were aged 
≥60 and had ≥3 CV risk factors. Median follow-up was 
60 months. Mostly mild GI bleeding events occurred 
in 0.97% of patients in the aspirin group versus 0.46% 
in the placebo group (HR 2.11; 95% CI 1.36-3.28; 
p=0.0007). Th e overall incidence of serious adverse 
events was 20.19% in the aspirin group and  20.89% 
in the placebo group. Th e overall incidence of adverse 
events was also similar in the two treatment groups. 
Th e overall incidence of treatment-related adverse 
events was 16.75% and 13.54% in the aspirin and pla-
cebo group (p<0.0001), respectively. Th e incidence of 
composite endpoint that included MI and stroke was 
about 4% in both groups. Th ere were 321 documented 
deaths in the intention-to-treat population, but diff e-
rence in the test groups was not signifi cant. Th e aut-
hors of the study concluded that the role of aspirin in 
primary prevention among patients at moderate risk 
could not be addressed (25). Nonetheless, the fi nd-
ings with respect to aspirin eff ects were consistent with 
those observed in the previously published low-risk 
primary prevention studies.
Th e results of the ASPREE trial were published in 
three separate articles (26-28). Th e goal of this ran-
domized, parallel and stratifi ed trial was to evaluate 
low-dose aspirin compared with placebo in healthy 
elderly patients. Th e trial involved 19,114 participants 
in Australia and the United States, aged ≥70 (or blacks 
and Hispanics aged ≥65) and free from CVD, demen-
tia, and disability at trial entry. Th ere were about 11% 
of patients with DM. Th e participants were randomly 
assigned to receive 100 mg daily of enteric-coated as-
pirin or placebo. Th e median duration of follow-up 
was 4.7 years. Th e rate of a composite of death, demen-
tia, or persistent physical disability was 21.5 events 
per 1000 person-years in the aspirin group and 21.2 
per 1,000 person-years in the placebo group (hazard 
ratio, 1.01; 95%CI, 0.92-1.11; p=0.79). Th ere was no 
signifi cant diff erence in the frequency of CVD (fatal 
CVD, MI, stroke, or hospitalization for heart failure) 
between aspirin treated subjects and those receiving 
placebo (10.7 events per 1,000 person-years in the as-
pirin group vs. 11.3 events per 1,000 person-years in 
the placebo group). All-cause mortality was 5.9% in 
the aspirin group versus 5.2% in the placebo group 
(p<0.05). Th e rate of major hemorrhage (8.6 events per 
1,000 person-years in the aspirin group vs. 6.2 events 
per 1,000 person-years in the placebo group; p<0.001), 
intracranial bleeding (2.5 events per 1,000 person-ye-
ars in the aspirin group vs. 1.7 events per 1,000 per-
son-years in the placebo group; p>0.05), and upper GI 
bleeding (2.1 events per 1,000 person-years in the as-
pirin group vs. 1.1 events per 1,000 person-years in the 
placebo group; p<0.05) was signifi cantly higher in as-
pirin treated patients (26-28). Based on these results, 
the authors of the research concluded that among he-
althy elderly patients, low-dose aspirin therapy was 
not benefi cial. Compared with placebo, aspirin did 
not improve disability-free survival or reduce major 
adverse cardiovascular events. Aspirin was associated 
with a signifi cant increase in major bleeding (attri-
buted to excess intracranial and upper GI bleeding), 
and an increase in all-cause mortality.
Similar to the ARRIVE trial (25), the ASPREE trial 
(26-28) showed no evidence for cardiovascular bene-
fi t of aspirin (hazard ratio for cardiovascular disease 
with aspirin vs. placebo, 0.95; 95%CI, 0.83-1.08), yet 
the risk of major bleeding was again higher with aspi-
rin than with placebo (hazard ratio, 1.39; 95%CI, 1.18-
1.62; p<0.001).
Very recently, Zheng and Roddick have reported re-
sults of a meta-analysis that included 13 trials with a 
total of 164,225 participants without CVD (29). Th e 
median age of trial participants was 62 years, 19% had 
DM, and the median baseline risk of primary cardio-
vascular outcome was 9.2% (range, 2.6%-15.9%). Th e 
primary cardiovascular outcome was a composite of 
cardiovascular mortality, nonfatal MI, and nonfatal 
stroke. Th e primary bleeding outcome was any major 
bleeding. Aspirin use was associated with signifi cant 
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reductions in the composite cardiovascular outcome 
compared with no aspirin (57.1 per 10,000 partici-
pant-years with aspirin and 61.4 per 10,000 partici-
pant-years with no aspirin) (HR, 0.89 [95% Cl, 0.84-
0.95]. Aspirin use was associated with an increased 
risk of major bleeding events compared with no aspi-
rin (23.1 per 10,000 participant-years with aspirin and 
16.4 per 10,000 participant-years with no aspirin) (29).
Aspirin tailoring therapy
Based on large-scale observational studies, low-dose 
aspirin (e.g., 100 mg daily) approximately doubles the 
risk of major extracranial bleeds, particularly upper GI 
hemorrhage (30). In the meta-analysis of individual 
participant data from 6 primary prevention trials per-
formed by the Antithrombotic Trialists’ Collaborati-
on, aspirin increased major GI and other extracranial 
bleeds by about half (0.10% vs. 0.07% per year; relati-
ve risk, 1.54; 95% Cl, 1.30-1.82; p<0.0001) (31), while 
signifi cant bleeding was signifi cantly less frequent in 
the secondary prevention trials. Interestingly, the main 
risk factors for coronary events, including DM, were 
also associated with hemorrhagic events, although for 
most the associations were slightly weaker for bleeding 
than for occlusive events (32). Th e benefi t/risk profi le 
of low-dose aspirin can vary substantially from an area 
of high risk where benefi ts clearly outweigh the excess 
of major bleeding complications to an area of low risk 
where the number of vascular events avoided equals 
the number of major bleeds caused by aspirin (33).
For primary prevention, in which risk is determined 
largely by age and presence or absence of DM, the 
benefi t-risk ratio for prophylactic aspirin in current 
practice is exceptionally small. Th us, beyond diet ma-
intenance, exercise, and smoking cessation, the best 
strategy for the use of aspirin in primary prevention of 
CVD may simply be to prescribe a statin instead (34). 
In contrast, for secondary prevention, in which risk 
is determined largely by the extent of atherosclerotic 
disease, the benefi ts of aspirin outweigh the risks of 
bleeding. Furthermore, in terms of safety, some medi-
cations (e.g., antiplatelet or anticoagulant drugs, sele-
ctive serotonin reuptake inhibitors, and nonsteroidal 
anti-infl ammatory drugs) may be considered absolute 
or relative contraindications to aspirin use for primary 
prevention because of their association with elevated 
bleeding risk (35-37). 
CONCLUSION
Even at low or very low doses, aspirin increases the risk 
of bleeding events. However, absolute excess bleed-
ing events will vary depending on individual baseli-
ne bleeding risks. Patient age is the strongest common 
risk factor for increased baseline bleeding, along with 
male gender, co-medications, and specifi c CBVD and/
or CVD risk factors. A history of GI ulcers or bleeding 
greatly increases the baseline risk of bleeding. Safe tre-
atment also implies eliminating patients using other 
medication that increase the risk of bleeding. For pa-
tients without safety concerns, aspirin is recommend-
ed in those with clear benefi t or on a case-by-case basis 
by considering preferences, values, and other poten-
tial benefi ts when potential benefi ts and harms seem 
closely balanced. Th erefore, on selecting the best can-
didates for prevention of CBVD and CVD, a gradual 
approach is required, during which candidates with 
the lowest risk of bleeding should be selected. Finally, 
aspirin may be considered for primary prevention of 
CBVD and CVD in both genders at a level of risk of 
major cardiovascular events (death, MI, and stroke) 
>2 per 100 subject-years, provided they have no clear 
evidence of increased risk of bleeding (GI bleeding or 
peptic ulcer disease, no concurrent use of other medi-
cations that increase bleeding risk). 
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Dnevna upotreba aspirina već je dugo poznata zbog svojih zaštitnih moždano- i srčanokrvožilnih učinaka, što je osobito 
izraženo u osoba s visokim rizikom (npr. osoba sa šećernom bolesti). Međutim, značajan broj istraživanja objavljenih u 
posljednjih pet godina dovodi u pitanje prednosti aspirina u primarnoj prevenciji moždano- i srčanokrvožilnih bolesti. Čim-
benici rizika za krvarenje iz probavnog sustava uzrokovanog aspirinom uključuju veću dozu i dugotrajno uzimanje lijeka, 
anamnezu o ulkusnoj bolesti, bolnost u žličici, poremećaje zgrušavanja krvi, zatajenje bubrega, tešku bolest jetre i trom-
bocitopeniju. Drugi čimbenici koji povećavaju rizik od krvarenja iz probavnog sustava ili moždano krvarenje u osoba koje 
uzimaju nisku dozu aspirina uključuju istodobnu uporabu antikoagulacijskih lijekova ili nesteroidnih protuupalnih lijekova, 
nekontroliranu hipertenziju, muški spol i stariju dob. Primarna prevencija moždano- i srčanokrvožilnih bolesti uzrokovanih 
aspirinom mora biti prilagođena svakom pojedinom bolesniku pri čemu treba uzeti u obzir omjer koristi i štete od uzimanja 
lijeka.
Ključne riječi: aspirin, moždano-krvožilna bolest, srčano-krvožilna bolest, primarna prevencija, sekundarna prevencija
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